ClinicalTrials.gg
RecruitingNCT07722013Updated Aug 6, 2026

Intermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension

An interventional study of Normal Saline and Ephedrine in Postinduction Hypotension, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Cairo University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing ephedrine in Hypotension — 4 open to participants now, 4 under way, none of them phase 3. Ephedrine · Hypotension.

Planned enrollment
10th of 22
124 · median 120
Started
2026
with 1 other
No phase
6 of 22
2 open now
Registered
22nd of 22
by date
Lead sponsor
2 of 22
Cairo University

Among the 22 studies testing ephedrine in Hypotension, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 with no phase, and was the 22nd registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

4 of the 22 studies testing ephedrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ephedrine

Ephedrine: first FDA approval 2016 (AKOVAZ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ephedrine in Hypotension, or all of them as a file.
02

Study summary

The aim of this work is to assess the efficacy of intermittent ephedrine boluses in prophylaxis against postinduction hypotension in high-risk patients undergoing major abdominal surgery, compared to standard care.

Read the detailed description

Fluid responders (≥20% rise in perfusion index on passive leg raising) will receive 500-mL Ringer's boluses (up to 1500 mL). Anesthesia will be induced with fentanyl/propofol, intubated after neuromuscular blockade, and maintained with isoflurane (1.2% end-tidal). Study drug will be given at induction and every 5 minutes for 20 minutes, withheld if MAP ≥80 mmHg or a recent vasopressor dose. Hypotension (MAP \<65 mmHg) will be treated with 0.1 mg/kg ephedrine boluses (max 9 mg single). Post-incision care follows anesthetist discretion.

03

Conditions studied

  • Postinduction Hypotension

Browse trials for

Keywords

  • major abdominal surgery
  • high risk patients
  • ephedrine
  • prophylaxis
  • postinduction hypotension
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged >50 years,
  • weight >50 kg,
  • (ASA) Physical Status score of > I,
  • undergoing major abdominal surgery

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac morbidities (impaired contractility with \< 40%, heart block, significant uncontrolled arrhythmias, tight stenotic valvular lesions)
  • Acute cardiovascular pathologies: acute/decompensated heart failure, acute coronary syndrome
  • Uncontrolled hypertension (systolic blood pressure>150 mmHg)
  • Preoperative HR more than 110 bpm despite proper fluid management and patients with renal impairment
  • Renal impairment
  • Patients on vasopressor infusion,
  • Allergy of any of the study drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Placebo comparator
    control

    Normal Saline boluses

    Drug: Normal Saline

  • Active comparator
    ephedrine

    ephedrine boluses

    Drug: Ephedrine

Interventions

  • DrugNormal Saline

    four 10-mL syringes of normal saline, The patient will receive the first dose of the intervention with induction (0.1 ml/kg). After induction of anesthesia, the study drug will be given every 5 min for 20 min and will be withheld if MAP was ≥80 mmHg or if any vasopressor is given within 2 min of the current scheduled dose

  • four 10-mL syringes of ephedrine 1 mg/mL. The patient will receive the first dose of the intervention with induction (0.1 ml/kg). After induction of anesthesia, the study drug will be given every 5 min for 20 min and will be withheld if MAP was ≥80 mmHg or if any vasopressor is given within 2 min of the current scheduled dose.

06

What researchers measure

Primary outcomes

  1. incidence of postinduction hypotension

    mean arterial pressure \< 65 mmHg

    Time frame: from induction of anesthesia until 20 minutes after induction

Secondary outcomes

  1. area under mean arterial pressure of 65 mmHg

    Time frame: from induction of anesthesia until 20 minutes after induction

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — data related to this protocol are available from principle investigator upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Jul 23, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722013
Lead sponsor
Cairo University
Responsible party
Ahmed Hasanin (Professor, Cairo University) — Principal investigator
First posted
Jul 23, 2026
Start date
Aug 4, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 6, 2026

Study contacts

Maha Mostafa, MD
Contact
maha.mostafa@cu.edu.eg
+201000365115

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ephedrine

Start the discussion